Abstract: Embodiments of the present invention generally relate to compositions and methods for treating acute or chronic bacterial infections of joints, tendons, ligaments, implants and associated soft tissues. In other embodiments, compositions of use herein generally relate to activated MSCs or iMSCs combined with antibiotics having reduced cytotoxicity for the treatment of bacterial infections of joints, tendons, ligaments, implants and associated soft tissue structures.

Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunostimulatory compositions disclosed herein can be directed to preventing or treating an infection, cancer or other immunocompromising health condition in the subject. In some embodiments, the immunostimulatory compositions disclosed herein enhance non-specific immune responses systemically or locally in the subject to treat or reduce the risk of onset of a health condition. In some embodiments, immunostimulatory compositions disclosed can be used to induce a non-specific immune response within mucosal surfaces such as the nasopharynx, upper respiratory tract, eye, GI tract, and reproductive tract to induce a non-specific immune response in order to reduce onset of or treat an infection or other health condition.

Abstract: Embodiments of the present invention relate to compositions and methods for activating canine OX40 to treat a condition in dogs. In certain embodiments, the condition can be cancer or an immunosuppressed condition in dogs and OX40 activation treats, ameliorates or prevents onset or progression of the condition. In other embodiments, compositions disclosed herein generally relate to compositions including, but not limited to, activating antibodies having specific affinity for OX40 for inducing activity of canine OX40. In other embodiments, compositions disclosed herein can be used for treating certain cancers or an immunosuppressed condition to treat the cancer or alleviate immunosuppression in dogs. In certain embodiments, other immune activators can be administered in combination with OX40 activating antibodies such as Toll-Like Receptor (TLR) ligands alone or in combination with other non-specific immunostimulant agents.

Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds of the eye.

Abstract: The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) in companion animals.

Abstract: Embodiments herein report compositions, methods, and uses for enhancing the immune system in a subject in need of such modulation/treatment. In certain embodiments, compositions and methods disclosed herein concern compositions that can include, but are not limited to, at least one agent capable of reducing the activation of, or blocking an angiotensin II receptor (ARB) and C-C chemokine receptor 2 (CCR2) and/or blocking a beta receptor (Beta Blocker, BRB), to induce and/or enhance immune response in subject. In certain embodiments, combination agents disclosed herein can enhance an immune response against cancer in a subject in need thereof. In other embodiments, combination therapies disclosed herein modify the tumor microenvironment (TME) to enhance effects of anti-cancer therapies as a combination therapy or used alone to modify the immune system of the subject to treat cancer in a subject.

Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds of the eye.

Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.

Abstract: A turbine engine air control valve including a valve body having a fluid flow passage and a valve member disposed in the valve body. The valve member is configured to rotate about a rotation axis between a maximum flow position and a minimum flow position. The valve member includes a vane and a floating member operatively coupled to the vane. The floating member is configured to float relative to the vane, such that when the valve member is in the minimum flow position, the floating member is spaced apart from the valve body to form an annular flow gap that provides a controlled amount of minimum fluid flow across the valve member as the fluid flows through the annular flow gap.

Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.

Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

Abstract: A windrow merger has a frame supporting first, second and third pickup assemblies, with the two outside pickup assemblies foldable between an extended use position and a retracted travel position. Each of the pickup assemblies includes a reversible conveyor providing multiple windrow merging configurations. The pickup assemblies are interchangeable and aligned to define an unobstructed pickup face.

Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.

Abstract: An inerting system and method characterized by a primary air separation module configured to communicate with an upstream source of pressurized air at elevated temperature for production of a primary downstream flow of nitrogen-enriched air to be delivered to a space to be inerted; a secondary air separation module configured to communicate with the upstream source of pressurized air at elevated temperature for production of a supplemental downstream flow of nitrogen-enriched air to be delivered to a space to be inerted when high nitrogen-enriched airflow is desired during a high flow period; and a flow controller configured to provide a warming flow through the secondary air separation module to heat the secondary air separation module to above ambient temperature during a warming period other than the high flow period.

Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.